These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2313204)

  • 1. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
    Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
    J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
    Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
    Vrablík M; Horínek A; Ceska R; Stulc T; Kvasnicka T
    Physiol Res; 2003; 52(5):647-50. PubMed ID: 14535841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
    Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
    Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
    Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
    Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue.
    Smit M; de Knijff P; Frants RR; Klasen EC; Havekes LM
    Clin Genet; 1987 Nov; 32(5):335-41. PubMed ID: 3690877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
    de Knijff P; van den Maagdenberg AM; Stalenhoef AF; Leuven JA; Demacker PN; Kuyt LP; Frants RR; Havekes LM
    J Clin Invest; 1991 Aug; 88(2):643-55. PubMed ID: 1864973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4.
    van den Maagdenberg AM; de Knijff P; Stalenhoef AF; Gevers Leuven JA; Havekes LM; Frants RR
    Biochem Biophys Res Commun; 1989 Dec; 165(2):851-7. PubMed ID: 2597162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.
    Pocovi M; Cenarro A; Civeira F; Myers RH; Casao E; Esteban M; Ordovas JM
    Atherosclerosis; 1996 Apr; 122(1):33-46. PubMed ID: 8724110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
    Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
    Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).
    Mann WA; Lohse P; Gregg RE; Ronan R; Hoeg JM; Zech LA; Brewer HB
    J Clin Invest; 1995 Aug; 96(2):1100-7. PubMed ID: 7635945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
    J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
    Heidemann BE; Koopal C; Baass A; Defesche JC; Zuurbier L; Mulder MT; Roeters van Lennep JE; Riksen NP; Boot C; Marais AD; Visseren FLJ
    Clin Genet; 2022 Oct; 102(4):253-261. PubMed ID: 35781703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.